May 11, at 4.45 p.m. Solvay will assume current marketing activities of SB and will execute a fully fledged product launch in new territories. This is an important business opportunity in line with the Solvay group strategy to increase its presence in Pharmaceuticals. The world-wide market for hypertension is estimated to be 10 billion US dollar, and therefore it is one of the most interesting areas for pharmaceutical marketing. It can cause progressive damage to the heart and the vascular system, leading to stroke, heart failure, myocardial infarction, and kidney disease.
Cardiovascular diseases are the leading cause of death in the western world.
The hypertension market is one of the largest single pharmaceutical markets world-wide. The group has a strong presence in Europe, and is growing rapidly in the US and Asia. Solvay Pharmaceuticals is part of the global chemical and pharmaceutical concern Solvay SA, headquartered in Brussels, Belgium. Solvay S.A. is present in 46 countries with about 33,000 employees. If you have any comments on this Website, please contact the Webmaster .